We examined the effects of the MDM2 inhibitor nutlin3a and its combination with the dual Bcl-2 and Bcl-xL inhibitor ABT-737, and the Bcr-Abl inhibitor nilotinib on BC CML patient samples. Here, MDM2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.